MODERNA INCMRNA
ASignal's systematic analysis rates MRNA as Neutral.
Reflects the latest available analysis · analyzed Oct 29, 2026
The case on MRNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health with low debt-to-equity ratio (0.19x)
- High cash reserves ($5.14B) providing operational flexibility
- Positive free cash flow ($299.25M)
- Current price above 20-day and 50-day moving averages
- Negative price momentum trend
- MACD below signal line indicating weakening bullish momentum
- Severely negative profitability metrics (net margin -141.43%, operating margin -557.93%)
- Extremely high valuation metrics (forward P/E -46.88x, P/S 38.38x)
- Low retail sentiment with only 6 Reddit mentions
Peers
Clustered with MRNA by analysis-profile similarity.
See the full verdict on MRNA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MRNA
Most investors never get a second opinion, let alone several. ASignal runs MRNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.